Dr. Carlsson’s research is focused on screening and early detection of prostate cancer. She is an investigator in the world’s largest randomized study of screening for prostate cancer, the European Randomized Study of Screening for Prostate Cancer. Dr. Carlsson’s research aims at finding a better balance between the harms and benefits of prostate-specific antigen (PSA) screening, through the use of multiplex testing and risk-stratified strategies that incorporate clinical information, biomarkers and magnetic resonance imaging. Her work on how the benefits and harms of prostate cancer screening varies by PSA levels at age 60 and how re-screening intervals can be adapted accordingly, was published in the British Medical Journal and has helped inform the screening guidelines in place at MSK as well as national guidelines. Dr. Carlsson is funded by a K22 career development award from the National Cancer Institute to study the psychology of decision making to better understand patients’ information needs, which will facilitate the development of better decision aids and lead to improved shared decision making.
View a full listing of Sigrid Carlsson’s journal articles.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Sigrid Carlsson discloses the following relationships and financial interests:
-
AdMeTech
Provision of Services (uncompensated) -
BJU International
Provision of Services -
Carden Jennings Publishing
Provision of Services -
Erasmus Conferences & Events S.A.
Provision of Services (uncompensated) -
European Association of Urology
Provision of Services (uncompensated) -
Journal of Sexual Medicine
Provision of Services
-
Malecare Inc.
Provision of Services (uncompensated) -
National Comprehensive Cancer Network
Provision of Services (uncompensated) -
Prevent Cancer Foundation
Provision of Services (uncompensated) -
Société Internationale d'Urologie (SIU)
Provision of Services -
Swedish Prostate Cancer Foundation
Provision of Services (uncompensated) -
Urology Times
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.
View all disclosures